These results are consistent with the reported ability of dabrafenib monotherapy to cause paradoxical hyperactivation of MEK (64), which we propose drives the pathogenic effects of SERCA2 deficiency and would explain the similar findings in biopsies of RAF inhibitor–induced Grover disease and DD. This evidence concerns the gene ATP2A2 and dentin dysplasia.